Can cholesterol drugs or hormone therapy shield hearts in endometriosis?

NCT ID NCT05059626

ENROLLING_BY_INVITATION Disease control Sponsor: Penn State University Source: ClinicalTrials.gov ↗

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This trial investigates whether simvastatin (a cholesterol-lowering drug) or Duavee (a hormone therapy) can improve blood vessel function in women aged 18–45 with endometriosis. Endometriosis is linked to higher heart disease risk, possibly due to inflammation. The study measures changes in skin and arm blood flow to see if either drug reduces that risk.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: simvastatin and bazedoxifene/conjugated estrogens (Duavee)
What this could lead to: If successful, this could point toward a way to reduce cardiovascular risk in women with endometriosis.
What could go wrong: This is a small, early-phase trial with only 28 participants, so results may not apply broadly. Both drugs have known side effects, and the benefit for heart health is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometriosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIOSIS

Contacts and locations

Locations

The John B. Pierce Laboratory

New Haven, Connecticut, 06519, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.